Literature DB >> 23925423

Who are the PDCO?

E M Dempsey1, K Connolly.   

Abstract

In January 2007, the Paediatric Regulation entered into force and established the Paediatric Committee (PDCO) within the European Medicines Agency. The goal of the PDCO is to improve the health of the children of Europe by increasing high-quality research for medicinal products and promoting the development and authorization of such medicines at the EU level. A major function of the PDCO is to formulate and authorize Paediatric Investigation Plans and Paediatric Use Marketing Authorisations. The EU's Seventh Framework Programme for Research has facilitated the establishment of consortia whose ultimate goal is to answer important clinical questions involving medicines commonly used "off-label", in children. The benefits of these consortia include enhanced collaboration amongst paediatricians, scientists and small to medium enterprises whose ultimate goal is to obtain an authorization for a new indication or formulation for use in the paediatric population. It will be interesting in a number of years time to measure the success of this very important European initiative.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23925423     DOI: 10.1007/s00431-013-2096-2

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  8 in total

1.  Feasibility of evaluating treatment of early hypotension in extremely low birth weight infants.

Authors:  Nestor Eduardo Vain; Keith J Barrington
Journal:  J Pediatr       Date:  2012-04-06       Impact factor: 4.406

2.  Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates.

Authors:  Girish Deshpande; Shripada Rao; Sanjay Patole; Max Bulsara
Journal:  Pediatrics       Date:  2010-04-19       Impact factor: 7.124

3.  Increased 36-week survival with high oxygen saturation target in extremely preterm infants.

Authors:  Ben Stenson; Peter Brocklehurst; William Tarnow-Mordi
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

4.  Diagnostic criteria and therapeutic interventions for the hypotensive very low birth weight infant.

Authors:  E M Dempsey; K J Barrington
Journal:  J Perinatol       Date:  2006-08-24       Impact factor: 2.521

5.  Feasibility study of early blood pressure management in extremely preterm infants.

Authors:  Beau J Batton; Lei Li; Nancy S Newman; Abhik Das; Kristi L Watterberg; Bradley A Yoder; Roger G Faix; Matthew M Laughon; Krisa P Van Meurs; Waldemar A Carlo; Rosemary D Higgins; Michele C Walsh
Journal:  J Pediatr       Date:  2012-02-14       Impact factor: 4.406

6.  Nasal CPAP or intubation at birth for very preterm infants.

Authors:  Colin J Morley; Peter G Davis; Lex W Doyle; Luc P Brion; Jean-Michel Hascoet; John B Carlin
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

7.  Early CPAP versus surfactant in extremely preterm infants.

Authors:  Neil N Finer; Waldemar A Carlo; Michele C Walsh; Wade Rich; Marie G Gantz; Abbot R Laptook; Bradley A Yoder; Roger G Faix; Abhik Das; W Kenneth Poole; Edward F Donovan; Nancy S Newman; Namasivayam Ambalavanan; Ivan D Frantz; Susie Buchter; Pablo J Sánchez; Kathleen A Kennedy; Nirupama Laroia; Brenda B Poindexter; C Michael Cotten; Krisa P Van Meurs; Shahnaz Duara; Vivek Narendran; Beena G Sood; T Michael O'Shea; Edward F Bell; Vineet Bhandari; Kristi L Watterberg; Rosemary D Higgins
Journal:  N Engl J Med       Date:  2010-05-16       Impact factor: 91.245

8.  Target ranges of oxygen saturation in extremely preterm infants.

Authors:  Waldemar A Carlo; Neil N Finer; Michele C Walsh; Wade Rich; Marie G Gantz; Abbot R Laptook; Bradley A Yoder; Roger G Faix; Abhik Das; W Kenneth Poole; Kurt Schibler; Nancy S Newman; Namasivayam Ambalavanan; Ivan D Frantz; Anthony J Piazza; Pablo J Sánchez; Brenda H Morris; Nirupama Laroia; Dale L Phelps; Brenda B Poindexter; C Michael Cotten; Krisa P Van Meurs; Shahnaz Duara; Vivek Narendran; Beena G Sood; T Michael O'Shea; Edward F Bell; Richard A Ehrenkranz; Kristi L Watterberg; Rosemary D Higgins
Journal:  N Engl J Med       Date:  2010-05-16       Impact factor: 91.245

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.